TABLE 1.

Clinical characteristics of reported cases of invasive scedosporiosis in patients with cystic fibrosis after lung transplantation^a

Patient	Age (yr)	Sex	Colonization before LTx	Antifungal prophylaxis after LTx	Time to diagnosis after LTx	Mycological organism identified	Antifungal agent(s)	Site(s)/clinical manifestation(s)	Survival time after diagnosis	Reference
1	27	M	NA	None	6 wkb	S. apiospermum/P. boydii	AMB	CNS	NA	2
2	24	F	No	None	7.5 mo	S. apiospermum/P. boydii	ITC-MIC	Heart, spleen, kidneys, CNS	4 wk	24
3	30	M	Yes	None	2 wk	S. apiospermum/P. boydii	AMB-MIC	Neuroria, pleuritis, pericarditis	1 wk	5
4	26	F	Yes	ITC, AMB	3 wk	S. apiospermum/P. boydii	VRC-MICc	Skin nodules, endophtalmitis, meningitis	6 mo	28
5	19	F	Yes	VRC	4 wk	S. apiospermum/P. boydii	VRC-CAS-TRB followed by POS	Skin nodules, endophtalmitis, pansinusitis, chest wall cellulitis, mediastinitis, vertebral osteomyelitis, septic arthritis	14 mo	26
6	37	F	Yes	VRC	8 wk	P. boydii	VRC-CAS-TRB	Skin nodules, endocarditis, CNS	6 mo	This article

^aThe outcome for all patients was death. M, male; F, female; NA, not available; ITC, itraconazole; MIC, miconazole; VRC, voriconazole; POS, posaconazole; AMB, amphotericin B; CAS, caspofungin; TRB, terbinafine; LTx, lung transplantation; CNS, central nervous system.

^bDiagnosis was made on brain biopsy.

^cIntraocular miconazole.